The Shelburne Group | Aleva Neurotherapeutics
21371
portfolio_page-template-default,single,single-portfolio_page,postid-21371,ajax_fade,page_not_loaded,,select-theme-ver-4.2,vertical_menu_enabled,no_animation_on_touch,wpb-js-composer js-comp-ver-7.6,vc_responsive
 

Aleva Neurotherapeutics

Aleva Neurotherapeutics develops the next generation of implantable Directional Deep Brain Stimulation systems based on MEMS technology.

Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. The first application is in Deep Brain Stimulation for indications such as Parkinson’s Disease and Essential Tremor.

Aleva was founded in 2008 as a spin-off of the Swiss Federal Institute of Technology in Lausanne, Switzerland. It has raised 46 MUSD to date from prominent VCs, strategic and private investors. Aleva is ISO13485 certified.

Visit Client Website